8 results
To determine if dose-intensifying the adjuvant temozolomide component of the chemoradiation treatment enhances treatment efficacy as measured by overall survival.
Determine whether temozolomide given during radiation therapy followed by the combination of temozolomide and CCNU as adjuvant therapy results in an improvement in event-free survival compared to historical control cohorts.To further assess the…
This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of crovalimab compared with placebo for the management of acute uncomplicated vaso-occlusive episodes (VOE) in patients with sickle cell disease (SCD).
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab compared with placebo as adjunct treatment for the prevention of vaso-occlusive episodes (VOEs) in patients with sickle cell disease (SCD).
This is a phase I study of hydroxyurea and dose-intense temozolomide in patients with recurrent glioblastoma that are elegise for re-challenge temozolomide.Primary Objective: To determine the maximal tolerated dose and safety profile of daily…
Primary objectives:- To evaluate whether the outcome in children, young people and adults with HR-MB is improved over standard therapy i.e. conventional (once a day) radiotherapy (RT) (standard therapy), for those treated with: hyperfractionated-…
PNET 5 MB-LR: Primary objective:-to confirm that the 3-year Event-Free Survival (EFS) rate in children and adolescents with standard-risk medulloblastoma having a low-risk biological profile remains in excess of 80% when patients are treated with 18…
Primary: To compare the efficacy of palbociclib in combination with TMZ and IRN vs TMZ and IRN chemotherapy alone in the treatment of children, adolescents, and young adults with recurrent or refractory EWS.Secundary: To further compare the efficacy…